[Page Banner Image]

The following is a review of developments affecting health care in Canada

The information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.

The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.

[HRule Image]

Healthcare in Canada - June 1998

The Board of Directors of Canadian Blood Services has announced the appointment of Ms. Lynda Cranston to the position of Chief Executive Officer (CEO) for the new blood agency. Ms. Cranston has been CEO, or a senior executive, with a variety of Canadian hospitals and health centres, principally in Western Canada. Her professional associations have included the Board of the Canadian College of Health Service Executives, the British Columbia Health Risk Management Society, the Hospital Administrators Association of British Columbia, the B.C. Provincial Health Utilization Committee, and the Council of University Teaching Hospitals. Most recently, Ms. Cranston has been Executive Vice-President and General Manager for Western Canada for Rogers Cantel Inc., a position that allowed her to hone her skills in customer relations and marketing.

The Minister of Health, the Honourable Allan Rock, released the 1997 Annual Report of the Patented Medicine Prices Review Board. According to the report, in 1997, prices of patented drugs were virtually unchanged from 1996, as compared to an increase in the Consumer Price Index (CPI) of 1.6%. Internationally, prices for patented drugs in Canada ranked third lowest, just below the United Kingdom. Since 1987, Canadian prices for patented drugs have declined 30% compared to foreign prices. Total sales by manufacturers of all drugs in Canada increased over 7% to $7.0 billion in 1997, while sales of patented drug products increased by over 20% to $3.7 billion. For the first time, patented drugs accounted for over 50% of the total sales of all drugs. R&D spending by pharmaceutical patentees in Canada increased to $725.1 million, while the R&D-to-sales ratio was virtually unchanged at 11.5%.
The report is available from Wayne D. Critchley, 1-877-861-2350, Tel: (613) 952-7622, Fax: (613) 952-7626

Vasogen Inc., Mississauga, has entered into a research collaboration with the University of Montreal Hospital Research Centre (CRCHUM), which includes Hotel Dieu, Notre Dame and St. Luc Hospitals. The Vasogen-CRCHUM research collaboration, with an estimated value of $2 million through the end of 1999, will be focused in the area of cardiovascular disease.

[HRule Image]

* Healthcare in Canada -May 1998
* Healthcare in Canada - April 1998
* Healthcare in Canada - March 1998
* Healthcare in Canada - February 1998
* Healthcare in Canada - January 1998
* Healthcare in Canada - July 1997
* Healthcare in Canada - June 1997
* Healthcare in Canada - May 1997
* Healthcare in Canada - April 1997
* Healthcare in Canada - March 1997
* Healthcare in Canada - February 1997
* Healthcare in Canada - January 1997
* Healthcare in Canada - December 1996
* Healthcare in Canada - November 1996
* Healthcare in Canada - October 1996
* Healthcare in Canada - September 1996
* Healthcare in Canada - August 1996
* Healthcare in Canada - July 1996
* Healthcare in Canada - June 1996

[HRule Image]

HomePage | Company Profile | Services | Research Reports Available
Product Developments Worldwide | Research News | Links

[HRule Image]
Send mail to stratcom@pagebleu.com with questions or comments about this web site.

Concept and Design Blue Page Productions
Copyright © 1996-1998 STRATCOM

Last modified: June 30, 1998